

# CITATION REPORT

List of articles citing

**Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy in the US.**

**DOI: 10.1080/13696998.2022.2065787**

**Journal of Medical Economics, 2022, , 1-37.**

**Source:** <https://exaly.com/paper-pdf/135979620/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1	Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. <i>Advances in Therapy</i> ,	4.1	1